ProfessorAlexander Menzies

BSc(Med) MBBS(Hons) FRACP PhD

Alexander Menzies is a Medical Oncologist and Associate Professor of Melanoma Medical Oncology at Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals. He has subspecialty interest in melanoma and breast cancer.

He received his PhD in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy, and has an impressive track record for clinical and translational research for this stage in his career. Since 2009 he has been an investigator on over 100 sponsored and investigator-led Phase I to III clinical trials of systemic therapies in melanoma and breast cancer, and in the last 5 years has over 100 publications with more than 6000 citations in journals such as Nature, Nature Medicine, Lancet Oncology, Nature Communications, Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research. He received the NSW Premier's Award for Outstanding Cancer Research Fellow in 2018.

A/Prof Menzies supervises several PhD students, conducts several investigator-led and sponsored clinical trials in melanoma and breast cancer, and manages the medical oncology clinical and biospecimen databases at MIA that underpin clinical and translational research. He serves as a Faculty member and Research and Clinical Committee member at MIA,Chairs the Department of Cancer Medicine at the Mater Hospital, Chairs the Melanoma and Skin Group for the Clinical Oncology Society of Australia (COSA), and serves as Faculty member for the European Society for Medical Oncology (ESMO) and Steering Committee member for the Society for Melanoma Research (SMR).He has co-established an international clinical research collaboration network between several major Australian, USA and European melanoma centres providing opportunities for junior research staff leading to high impact original research publications, and is a founding member of the international neoadjuvant melanoma consortium (INMC).He speaks regularly at national and international scientific meetings.

His main research interests are clinical trials of new systemic therapies for melanoma and breast cancer, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity.